表 1.

两组患者的特征对比

Comparison of characteristics between the two groups of cases

Case	Age at diagnosis	Gender	Smoking history	Pathological type of the first biopsy	First-line treatment modalities	Evaluation of best overall response	Pathological type of secondary biopsy	PFS before small-cell transformation	PFS after small cell transformation	OS
LUAD: lung adenocarcinoma; SD: stable disease; PR: partial response; PFS: progression-free survival; OS: overall survival; SCLC: small cell lung cancer.
Case 1	73	Female	No	LUAD	Gefitinib	SD	SCLC	16 mon	6 mon	Not appear
Case 2	60	Male	Yes	LUAD	Afatinib	PR	SCLC	24 mon	8 mon	36 mon